A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jordi Rodon, MD
Hospital Universitario Vall d´Hebron
Principal Investigator - Jose Baselga, MD
Massachusetts General Hospital
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hospital Universitario Vall D´hebron
Barcelona, Spain
- Hospital Universitario 12 de Octubre
Madrid, Spain
- Hospital Clínico Universitario de Valencia
Valencia, Spain
- Instituto Valenciano de Oncología
Valencia, Spain
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Dana-Farber at Faulkner Hospital
Boston, Massachusetts, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jun 2012
- Primary completion
- 31 Oct 2015
- Completion
- 31 Oct 2015
- Last update posted
- 28 Oct 2020
- Registered enrollment
- 50
- Registry id
- NCT01629615
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.